Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
About us
Contact
Links
About us
Contact
Links
Accordion Title
Accordion Content
more items +
An active fund holding a whopping 800 stocks is beating major indexes. Here’s how.
Social Security recipients will get more money next year. Here’s how much benefits may rise.
Lumentum’s stock surges, giving a further boost to the optical-networking trade
CoreWeave’s stock is rocketing after earnings lead to praise from bulls and bears alike
Nebius adds to the excitement around neocloud stocks with upbeat earnings of its own
Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
The $30 trillion Treasury market is facing a painful reckoning. How rising yields could squeeze your portfolio.
This week’s solar eclipse could make stocks go down. No, really. Here’s why.
Citadel Securities called the stock-market reset. Now it sees a leverage buildup on the horizon.
Super Micro stock is rallying after results. Here’s what Wall Street is saying.
AI capex could hit $1.6 trillion next year, says fund manager who sees more echoes of 1998 than the dot-com bust
Another AI lab is burning through cash as Tencent earnings rise
An active fund holding a whopping 800 stocks is beating major indexes. Here’s how.
Social Security recipients will get more money next year. Here’s how much benefits may rise.
Lumentum’s stock surges, giving a further boost to the optical-networking trade
CoreWeave’s stock is rocketing after earnings lead to praise from bulls and bears alike
Nebius adds to the excitement around neocloud stocks with upbeat earnings of its own
Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
The $30 trillion Treasury market is facing a painful reckoning. How rising yields could squeeze your portfolio.
This week’s solar eclipse could make stocks go down. No, really. Here’s why.
Citadel Securities called the stock-market reset. Now it sees a leverage buildup on the horizon.
Super Micro stock is rallying after results. Here’s what Wall Street is saying.
AI capex could hit $1.6 trillion next year, says fund manager who sees more echoes of 1998 than the dot-com bust
Another AI lab is burning through cash as Tencent earnings rise
I wanted to transfer $17,000 in credit-card debt. Why did Wells Fargo offer me only a $4,000 credit limit?
22-07-26
“I asked why the limit was so low, but they couldn’t give me an explanation.”
Share this on:
